Allergan/MAP Planned Merger, Approval Of NuPathe’s Triptan Patch Change U.S. Landscape For Migraine Therapy
Executive Summary
While Allergan plans to diversify its portfolio in migraine by acquiring partner MAP and its candidate for acute migraine, NuPathe seeks a partner for a triptan patch product expected to avoid the nausea suffered by many migraine patients.
You may also be interested in...
Zecuity Redesign Got Migraine Patch Through FDA, But Burning Continued
FDA worries about burning and scarring with the battery-powered Zecuity patch prompted NuPathe to reconfigure the drug-device combo; our Drug Review Profile shows how FDA thought the problem was solved, but adverse reaction reports soon after launch led to marketing suspension.
Deals Of The Week: Eisai Shares Full Compound Library In Screening Partnership With JHU
Academic drug-discovery collaborations with industry usually are limited by restraints companies place on how much of their compound libraries they’ll share in a collaboration. Plus the week’s top deals, including M&A transactions between Teva and NuPathe, and Par Pharmaceuticals and JHP.
With Or Without Generic Competition, Allergan’s CEO Sees Growth Ahead
Prospects for its key ophthalmic drug Restasis are still up in the air, despite recent positive news, but Allergan CEO expects double-digit sales and earnings growth for the next five years, driven by operating efficiencies and creation of new markets.